During most eye infections or injuries, neutrophils, immune cells found in the blood, are usually the first line of defense.

Summary: Unlike most tissues, the retina doesn’t summon neutrophils—the body’s typical first responders—when injured. Instead ...

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering ...

During most eye infections or injuries, neutrophils, immune cells found in the blood, are usually the first line of defense. However, researchers at ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Meet 12 biotech companies with promising genetic disease therapies that successfully closed funding rounds recently.

Plus Nanoscope Therapeutics applies for FDA approval and Metrocrest Hospital Authority's nonprofit grants.

US FDA accepts resubmitted NDA of Aldeyra Therapeutics for review of topical ocular reproxalap to treat dry eye disease: Lexington, Massachusetts Saturday, July 19, 2025, 13:00 Hr ...

The vision research community rallies to protect the National Eye Institute from funding cuts, emphasizing its vital role in preventing blindness and advancing treatments.

RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE PARK, N.C., July 23, 2025 ...

The pace of quarterly reports is stiffening and in the main, like a lamington, the news is easy to digest for ASX biotech investors.

LEXINGTON, MA, USA I July 16, 2025 I Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New ...